-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Over the past few decades, the mortality rate from prostate cancer has declined
due to the popularity of early identification of PSA screening and advances in medical and surgical management.
However, some male patients experience initial biochemical remission after surgery, but eventually biochemical failure and may continue to develop metastatic disease
.
Salvage radiation therapy (SRT) is indicated for biochemical failure
following radical prostatectomy.
Previous data suggest that initiating SRT therapy at lower PSA levels improves subsequent biochemical control, although the optimal timing of SRT treatment remains in question
given the long natural history of prostate cancer.
Recently, researchers from the United States published an article in Prostate investigating the effect of prostate-specific antigen (PSA) levels during salvage radiotherapy on relapse-free survival (bRFS) and metastasis-free survival (MFS) in patients with biochemical relapse.
Using prospective institutional tumor registry data, the researchers constructed univariate and multivariate-adjusted Cox proportional risk models to assess the association between treatment outcomes and clinical and pathologic prognostic features, including pre-SRT PSA, interval from prostatectomy to SRT, androgen deprivation therapy (ADT), and adverse pathologic features
.
The study included 397 patients
who received salvage RT between 1985 and 2016.
In 187 (45.
8%) patients, PSA ≤ 0.
5 ng/ml before initiating SRT therapy; In 212 (52.
0%) patients, PSA > 0.
5 ng/ml
before initiating SRT.
Independent of pathologic risk status and ADT use, pre-SRT PSAs ≤ 0.
5 ng/ml were the most important predictors of
bRFS (HR = 0.
39, 95% CI [0.
27 to 0.
56]) and MFS (HR = 0.
58, 95% CI [0.
37 to 0.
91]).
Seminal vesicle invasion is also associated
with shorter intervals of biochemical defeat (HR = 1.
79, 95% CI [1.
07 to 2.
98]) and final metastasis (HR = 2.
07, 95% CI [1.
14 to 3.
740]).
Biochemical relapse-free survival in different subgroups
In summary, initiation of salvage RT at PSA levels of ≤ 0.
5 ng/ml was associated with
MFS improvement.
Therefore, it is necessary to initiate salvage RT when PSA levels are low, which reduces the risk of
future prostate cancer metastasis.
Original source:
Emerson E Lee, Tanmay Singh, Chen Hu et al.
The impact of salvage radiotherapy initiation at PSA ≤ 0.
5 ng/ml on metastasis-free survival in patients with relapsed prostate cancer following prostatectomy.
Prostate.
Oct 2022